The short answer: the label is a loophole, not a safety standard
“For research use only” and “not for human consumption” are disclaimers, not quality grades. They let a seller avoid the rules that apply to medicines while hinting that the powder inside is the same thing your clinician would use. The FDA’s position is that it often is not, and that you cannot tell.
In its page on unapproved GLP-1 drugs, last updated in October 2026, the FDA says it has warned companies that illegally sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide falsely labeled “for research purposes” or “not for human consumption.” Those products were sold directly to consumers for human use, with dosing instructions. The agency urges people not to buy them because their quality is unknown.
What can be wrong with a research-labeled vial
No approved drug review, pharmacy license or batch testing stands behind these products. The FDA describes the risks of illegally marketed semaglutide and tirzepatide in plain terms: they may be counterfeit, may contain the wrong or harmful ingredients, and may contain too little, too much or none of the active drug.
| Problem | Why it matters |
|---|---|
| Wrong or unknown ingredient | You may be injecting something other than semaglutide or tirzepatide |
| Too much active drug | Higher doses bring more nausea, vomiting and dehydration |
| Too little or none | No effect, and a temptation to keep raising the dose |
| Contamination | A non-sterile injection can cause infection |
| Salt forms | The FDA says semaglutide sodium and acetate are different active ingredients with no known lawful basis for compounding |
| Poor storage | Injectable GLP-1s need refrigeration; the FDA advises against using any that arrive warm |
Multi-dose vials raise one more issue. The FDA recommends discarding a vial of sterile injectable medicine within 28 days of first use, even if some remains, and using a new sterile needle and syringe for every dose. A research powder carries no pharmacy beyond-use date, so there is no reliable guide to how long a mixed vial stays safe to use.
Retatrutide deserves its own mention because it shows up often on research-chemical sites. The FDA notes it is not a component of any approved drug, has not been found safe and effective for any condition, and cannot be used in compounding under federal law.
Counterfeit pens are a separate risk
Not every fake looks like a powder. The FDA states it is aware of counterfeit Ozempic marketed in the United States, and counterfeit drugs can contain the wrong ingredients or the wrong amount. It has also found fraudulent compounded semaglutide and tirzepatide with labels naming pharmacies that do not exist, or real pharmacies that never made the product.
A pen bought from a social media seller, an overseas website or a friend skips the pharmacy chain that makes recalls and lot tracing possible. If the price is far below anything you have seen elsewhere, the FDA lists that as a warning sign in itself.
Why mixing a powder at home multiplies dosing errors
Research products usually arrive as dry powder that you dissolve yourself, then measure into a syringe. Every step adds a chance for error: the true amount of drug in the vial, the volume of liquid you add, and converting a milligram dose into syringe markings.
The FDA has already seen this play out with compounded semaglutide, which is at least made by a licensed pharmacy. It has received reports of adverse events, some requiring hospitalization, linked to patients measuring and self-administering the wrong dose, and in some cases to health care professionals miscalculating doses. Reported symptoms included nausea, vomiting, diarrhea, abdominal pain and constipation. With a research powder of unknown strength, even perfect measuring cannot fix a wrong starting concentration.
Where legitimate compounding stands in 2026
The shortages that once allowed widespread compounding of these drugs are over. In an April 2026 update, the FDA noted that semaglutide and tirzepatide are on neither its drug shortage list nor the 503B bulks list, which limits outsourcing facilities. State-licensed pharmacies may still compound for an individual patient, but not routine copies of a commercially available drug.
Side effects from compounded versions are tracked too. As of May 31, 2026, the FDA had received 990 adverse event reports tied to compounded semaglutide and more than 730 tied to compounded tirzepatide. The agency notes these are likely undercounts, because state-licensed pharmacies that are not outsourcing facilities do not have to report adverse events to it. Research-labeled products sit outside even that partial system.
Even lawful compounded drugs are not FDA-approved, and the FDA’s compounding questions and answers say they should only be used when an approved drug cannot meet a patient’s medical need. Our explainer on 503A and 503B pharmacies covers how those two types of pharmacy are regulated, and our page on compounded GLP-1 rules follows the policy changes in detail.
Red flags before you buy anything online
The FDA’s list of warning signs applies to any website or telehealth seller. Be cautious if a company:
- claims a compounded or research product is the same as an FDA-approved drug;
- offers deep discounts or prices that seem too good to be true;
- ships medicine that looks different from before, arrives damaged, or comes without instructions;
- provides medicine without a medical screening by a licensed clinician;
- has no licensed clinician available to answer questions afterward;
- has spelling errors on the label or lists a pharmacy address that does not check out.
What supervised treatment includes instead
Supervised care trades the guesswork for a known product, a dose set by a clinician, and someone who notices early when something is off. At Ultimate Male, medical weight loss starts with a medical evaluation, labs before semaglutide or tirzepatide and a body composition analysis, followed by regular check-ins.
If you have been using a research product, tell us exactly what it was, how you measured it and how you felt. That history changes how cautiously a new plan should start. Our GLP-1 warning signs guide lists the symptoms that need a same-day call, and the free 10-minute phone call is the easiest place to begin.
